Aradigm (ARDMQ) Stock Price, News & Analysis

Company Overview

Aradigm Corp. is a leading developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. Their hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via the lung.

Key Stats

• Today's Range: $0.05 to $0.05
• 50-Day Range: $0.05 to $0.05
• 52-Week Range: $0.02 to $0.20
• Volume: N/A
• Average Volume: 21,923 shs
• Market Capitalization: $764,000.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ARDMQ Stock Analysis - Frequently Asked Questions

How have ARDMQ shares performed this year?

Aradigm's stock was trading at $0.05 at the start of the year. Since then, ARDMQ stock has increased by 0.0% and is now trading at $0.05.
View the best growth stocks for 2025 here.

How do I buy shares of Aradigm?

Shares of ARDMQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 3/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Electromedical Equipment
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:ARDMQ
• CIK: N/A
• Web: www.aradigm.com
• Phone: 510-265-9000
• Fax: 510-265-8878
• Employees: 23
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 15,280,000
• Free Float: N/A
• Market Cap: $764,000.00
• Optionable: Not Optionable
• Beta: N/A